The LAAO Paradox: Lessons from the CLOSURE-AF Trial

For years, Left Atrial Appendage Occlusion (LAAO) has been the primary alternative for atrial fibrillation (AF) patients who cannot tolerate long-term anticoagulation. However, new data from the CLOSURE-AF trial, recently published in the New England Journal of Medicine, is shifting the clinical narrative.

In a surprising result, the study found that for patients at high risk for both stroke and bleeding, standard medical care (predominantly DOACs) was actually superior to the LAAO procedure.

Key Clinical Findings

The study followed 912 high-risk patients over a median of three years, revealing several critical insights:

 * Failure of Noninferiority: LAAO did not meet the statistical criteria to be considered "just as good" as medical therapy.

 * Higher Event Rates: The LAAO group saw 16.83 events per 100 person-years (composite of stroke, embolism, major bleeding, and CV death) compared to 13.27 in the medical care group.

 * Periprocedural Risk: A significant portion of the bleeding events in the LAAO arm occurred during or immediately after the procedure itself.

Why the Shift?

While some experts argue that next-generation devices and increased operator experience might yield different results today, the trial highlights that modern medical therapy is a formidable "gold standard." For high-risk populations, the immediate surgical risks must be more carefully weighed against the long-term efficacy of DOACs.

The Bottom Line: While LAAO remains a vital tool, CLOSURE-AF serves as a reminder that medical management is often the safer, more effective route for our most vulnerable patients.

Journal Reference

Landmesser U, et al. Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding. New England Journal of Medicine. 2026.